<DOC>
	<DOCNO>NCT02795988</DOCNO>
	<brief_summary>The Phase 1b study open-label , multicenter dose escalation study design assess safety , tolerability , immunogenicity recommend phase 2 dose ( RP2D ) IMU-131 . The RP2D evaluate dose expansion Phase 2 study .</brief_summary>
	<brief_title>A Study IMU-131 Plus Standard Care Chemotherapy Patients With HER2/Neu Overexpressing Advanced Cancer Stomach</brief_title>
	<detailed_description>IMU-131 single peptide structure compose 3 individual B-cell epitope peptide sequence select HER2/neu structure . Polyclonal antibody IMU-131 peptide bind three separate region HER2 receptor also dimerization loop HER2 receptor , prevent dimerization , turn inhibits intracellular signal . This blockade HER2 signal pathway think substantially great trastuzumab alone . Safety immunogenicity 3 peptide show Phase 1a test early formulation IMU-131 . The shelf stability Phase 1a vaccine optimal hence formulation adjust IMU-131 . The three B-cell epitope peptide ( P4 , P6 P7 ) combine specific order result single fusion peptide 49 amino acid length ( P467 ) . This new formulation IMU-131 extend stability improve immunogenicity compare formulation use previously . The new vaccine IMU-131 produce strong rapid polyclonal antibody response efficient manufacture compare previous formulation . Based three know epitope ( P4 , P6 P7 ) , investigator develop single peptide antigen ( P467 ) , allow simplification manufacturing process . It hypothesize administration IMU-131 addition chemotherapy prolong survival may delay tumor progression and/or reduce tumor burden patient HER2/neu overexpressing gastric gastroesophageal junction ( GEJ ) adenocarcinoma ( otherwise know Advanced Cancer Stomach ( ASC ) ) . The Phase 1b study aim determine safety tolerability IMU 131 identify Recommended Phase 2 Dose ( RP2D ) IMU 131 combination chemotherapy HER2/neu overexpressing ACS carry Phase 2 dose expansion study . The Phase 2 component submit amendment initiate follow completion Phase 1b . Phase 2 design characterize safety explore clinical activity IMU-131 combination chemotherapy HER2/neu overexpressing ACS .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Patient inform investigational nature study give write informed consent accordance institutional , local , national guideline ; 2 . Age ≥ 20 year old ; 3 . Life expectancy least 12 week ; 4 . No prior chemotherapy radiotherapy advance gastric GEJ cancer within 6 month prior Day 0 ; 5 . Metastatic gastric GEJ adenocarcinoma , locally advanced disease amenable surgical resection ; 6 . HER2/neu overexpression ( 3+ immunohistochemistry ( IHC ) IHC 2+ confirmed fluorescent situ hybridization [ FISH ] chromogenic situ hybridization [ CISH ] ) ; 7 . ECOG performance status 01 ; 8 . At least one measurable lesion define RECIST 1.1 criterion ; 9 . Adequate leave ventricular ejection function baseline , define LVEF &gt; 50 % echocardiogram MUGA scan ( Multi Gated Acquisition Scan ) ; 10 . Adequate hematologic function : absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L , platelet count ≥ 100 x 109/L , hemoglobin ≥ 9 g/dL ; 11 . Adequate liver function evidence bilirubin ≤ 1.5 x laboratory upper limit normal [ ULN ] , ALT AST ≤ 3 x laboratory ULN liver involvement ALT AST ≤ 5 time laboratory ULN liver involvement ; 12 . Adequate renal function ( creatinine ≤ 1.5 x laboratory ULN ) ; 13 . Willing able comply schedule visit , treatment plan , laboratory test , study procedure . 14 . Male female patient childbearing potential must agree use highly effective method contraception throughout study least 28 day last dose assign treatment ( see section 4.3 detail ) . A patient childbearing potential , opinion investigator , he/she biologically capable child sexually active . 1 . Previous treatment trastuzumab HER2/neu target antibody agent ; 2 . Continuous systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 4 week prior first dose study treatment . Inhaled topical steroid physiological replacement dose 10 mg daily prednisone equivalent permit absence active autoimmune disease ; 3 . Prior organ transplant ; 4 . Patient consider candidate 5FU , capecitabine , cisplatin chemotherapy ; 5 . History document congestive heart failure ; angina pectoris require antianginal medication ; evidence transmural infarction ECG ; poorly control hypertension ; clinically significant valvular heart disease ; high risk uncontrolled arrhythmia ; New York Heart Association ( NYHA ) class II heart disease ; 6 . If warfarin ( Coumadin® ) vitamin K antagonists ; 7 . Concurrent active malignancy except adequately control limited basal cell carcinoma skin ; 8 . Peripheral neuropathy hearing loss NCI CTCAE Grade &gt; 2 ; 9 . History uncontrolled seizure , central nervous disorder psychiatric disability judge investigator clinically significant precluding informed consent , participation study , adversely affect compliance study drug ; 10 . Active infection require IV antibiotic ; 11 . Positive human immunodeficiency virus ( HIV ) ( HIV 1/2 antibody ) active hepatitis B ( HBsAg reactive ) active hepatitis C ( HCV ribonucleic acid [ RNA ] qualitative ) infection ; 12 . Pregnant lactating female ; 13 . Major surgery within 4 week prior study entry . Minor surgery ( exclude diagnostic biopsy ) within 1 week prior study entry ; 14 . Has receive livevirus vaccination within 4 week first study vaccination . Seasonal flu vaccine contain live virus permit ; 15 . Current recent ( within 4 week first IMU131 vaccination ) treatment another investigational drug participation another investigational study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Secondary</keyword>
</DOC>